anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Type 2 diabetes is a chronic, metabolic disease characterized by hyperglycemia resulting from insulin resistance. Research studies indicate that complications such as cardiovascular disease, peripheral vascular disease, retinopathy, and loss of physical function are associated with type 2 diabetes. Clinical management of people with type 2 diabetes consists of medical nutrition therapy, pharmacological therapy, and exercise. Exercise has been shown to improve risk factors associated with complications of type 2 diabetes such as elevated plasma glucose, elevated blood pressure, loss of muscular strength, and loss of exercise capacity. In fact, the American Diabetes Association and American College of Sports Medicine have published position statements recommending the use of exercise, specifically resistance and aerobic training, as an intervention for people with type 2 diabetes. However, 31 percent of people with type 2 diabetes have reported no regular physical activity and an additional 38 percent have reported less than recommended levels of physical activity. Therefore, interventions to promote regular exercise behavior in people with type 2 diabetes are clinically important by potentially preventing type 2 diabetes-related complications.

Previous studies have investigated the impact of exercise counseling on exercise behavior in people with type 2 diabetes. However, these studies have limitations such as lack of agreement with exercise training guidelines for people with type 2 diabetes and research design flaws. This current study investigates the effect of a novel, physical therapist-directed exercise counseling combined with fitness center-based exercise training intervention on stage of exercise behavior in people with type 2 diabetes.
BACKGROUND & AIMS: Chronic gastrointestinal (GI) symptoms are a common reason for seeking medical care. We aim to determine the rates of ambulatory care use and to characterize demographics, work-up, and treatment (pharmacologic and nonpharmacologic) for patients with chronic upper GI symptoms and conditions in the United States.
METHODS: Estimates of annual visits for the most common upper GI symptoms and diagnoses including gastroesophageal reflux disease, dyspepsia, nausea and vomiting, and gastroparesis were recorded from the 2007-2015 National Ambulatory Medical Care Surveys. Only chronic conditions, defined as >3 months, were included. We calculated the weighted proportion of ambulatory visits associated with pharmacologic, nonpharmacologic treatment (eg, diet, complementary and alternative medicine), or both.
RESULTS: A total of 116,184,475 weighted ambulatory visits were identified between the years of 2007 and 2015 for adults (average of 12,909,386 annual visits) with chronic upper GI symptoms and diagnoses. Gastroesophageal reflux disease was the most common reason for an ambulatory visit (n = 11,200,193), followed by dyspepsia (n = 1,232,598), nausea and vomiting (n = 714,834), and gastroparesis (n = 140,312). Pharmacologic treatment was more common than nonpharmacologic treatment (44.7% vs 28.5%). A total of 37.6% of patients were not receiving treatment at the time of the visit. These treatment patterns did not significantly change over the time of our study. Upper endoscopies were the most ordered test, representing 7.5% of all investigated upper GI symptoms.
CONCLUSIONS: Chronic upper GI symptoms and diagnoses account for a high number of annual health care visits, both in primary care and specialty care. Although there are several treatments, many of these patients are not on any treatments.
The invention discloses a microcapsule of nosiheptide and a process for preparation. The microcapsules take nosiheptide ethanol raffinate as the core, gelatin as plasticizer, beta-cyclodextrin as lubricant, and tween-80 as surface activator. The quality proportion of nosiheptide ethanol raffinate and gelatin, beta-cyclodextrin is 1:3-1:6, the quality proportion of gelatin and beta-cyclodextrin is 3-4, the water solution concentration of gelatin is 20-40mg/ml, and the dosage of tween-80 is 1-3% of the whole volume. The process for preparation contains making the gelatin into water solution, charging 1/3-1/4 of lubricant, magnetic stirring under the constant temperature of 50 DEG C, dripping surface activator, mixing them quickly and evenly into aqueous phase, then bringing nosiheptide ethanol as oil phase, dripping contract into the aqueous phase at the speed of 60 drops per minute and getting O/W emulsion, drying the prepared emulsion by spray. Finally the microcapsules are prepared. The prepared microcapsules has the advantages of even granule of microcapsule with average granule diameter of 5+-0.5mum, having no peculiar smell in 180 seconds, and no sense of gravel, which improves the conformability of animals, and provides convenience to animals.
HYZAAR can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue HYZAAR as soon as possible.

Thiazides cross the placental barrier and appear in cord blood. Adverse reactions include fetal or neonatal jaundice, thrombocytopenia [see Use in Specific Populations (8.1)].
A cloud-based system/expert system and method to provide healthcare management utilizing blockchain are disclosed. The system comprises a computing device including a processor and a memory in communication with the processor, a database in communication with the computing device, and a user device associated with a user. The computing device is configured to collect healthcare information of the user. The computing device further configured to analyze and assimilate the collected healthcare information. The analyzed healthcare information is compared with the optimal and average health metrics of same sex, race, and demography, etc. Upon comparison, the system generates a healthcare report of the user in a format understandable to a non-medically trained person. Further, the system provides suggestions and recommendations in the health report to improve the current health status of the user.
BACKGROUND: Mycobacterium haemophilum has been increasingly found in severely immunocompromised patients but is scarcely reported in immunocompetent adults.
METHODS: We systematically reviewed previous literature to identify studies on infection in immunocompetent adults. Articles reporting at least one case of M. haemophilum infection were included. We excluded articles involving patients who had immunosuppression-related diseases and routinely used glucocorticoids or immunosuppressants. We also reported a case of a young immunocompetent woman infected by M. haemophilum along the eyebrows, which was probably due to the use of an eyebrow pencil retrieved from a sink drain.
RESULTS: Twelve qualifying articles reporting M. haemophilum infection in immunocompetent adults were identified. Among them, most cases report skin lesions along the eyebrows, and the remaining had cervicofacial lymphadenitis, lesions on the arm or fingers, inflammation in the eyeballs, or ulceration in the perineal region. Most cases were caused by tattoos, make-up, injury, or surgical operation. For diagnosis, specialized tissue culture sensitivity was roughly 75%, and polymerase chain reaction (PCR) test sensitivity was approximately 89%. Triple antibiotic therapy for 3 to 24 months, or surgical excision was effective in controlling infection.
CONCLUSION: M. haemophilum infection should be considered if routine antibacterial and glucocorticoid treatments are ineffective against the disease, even in healthy adults. To definitively diagnose this infection, conditioned tissue culture or PCR testing is required. Treatment usually involves a combination of multiple antibiotics and, if necessary, surgical removal of infected tissue.
Patients who were previously enrolled in a vibrotactile study meant to reduce symptoms associated with Parkinson's disease will be enrolled in the study and will be asked to stimulate with the Stanford Coordinated Reset(CR) glove in sessions that last 2 hours. Sessions may be daily or a few times weekly depending on the needs of the patient.
Worldwide, and especially in Mexico, there is a high incidence of diabetes mellitus (DM), which in turn, confers a higher cardiovascular risk in this population. Diabetic patients undergoing PCI have worse outcomes than non-diabetics regardless of the degree of complexity of their coronary anatomy. Although the 30-day in-hospital outcomes have been similar between diabetic and non-diabetic patients, DM has been invariably associated with greater stent failure with target vessel revascularization (TVR), major adverse cardiovascular event (MACE), and mortality in the long-term follow-up, even with the use of drug-eluting stents. In relation to the above, two of the sirolimus-eluting stents (SES): the Abluminus and the Orsiro, have been considered as promising options in patients with DM. The Abluminus stent has been designed for diabetic patients in order to reduce cardiovascular events. Said stent consists of a cobalt-chromium platform covered with a layer of biodegradable polymer and mounted on a balloon, both sirolimus-releasing. The Rate of target lesion failure (TLF) reported to date in diabetic patients is 3.8%. On the other hand, the Orsiro stent, a cobalt-chromium platform with ultrathin struts, has had favorable results in different clinical settings and patients with different characteristics\]; specifically in a subgroup analysis in DM, a TLF rate of 3.5% was reported
Vilazodone treatment. Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional). Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects. Twelve weeks of treatment, total.
A method of automatically diagnosing pneumonia in a patient includes using an input/output interface device to obtain values of two or more diagnostic parameters of the patient from a caregiver for the patient. The method includes using a processor coupled to the input/output interface to apply the two or more diagnostic parameters to an electronic memory storing precompiled pneumonia diagnostic models to identify an optimal diagnostic model for making a diagnosis. The values of the two or more diagnostic signs are applied to the identified optimal diagnostic model to generate a diagnosis output. The input/output interface device is operated in accordance with the diagnosis output to indicate the presence or absence of pneumonia in the patient to the caregiver. The caregiver may use the diagnosis to provide appropriate care to the patient. The pneumonia diagnostic models are derived from investigation of a population of pneumonia positive and non-pneumonia subjects.
BACKGROUND: Cardiac hypertrophy is an intermediate stage in the development of heart failure. The structural and functional processes occurring in cardiac hypertrophy include extensive gene reprogramming, which is dependent on epigenetic regulation and chromatin remodeling. However, the chromatin remodelers and their regulatory functions involved in the pathogenesis of cardiac hypertrophy are not well characterized.
METHODS: Protein interaction was determined by immunoprecipitation assay in primary cardiomyocytes and mouse cardiac samples subjected or not to transverse aortic constriction for 1 week. Chromatin immunoprecipitation and DNA sequencing (ChIP-seq) experiments were performed on the chromatin of adult mouse cardiomyocytes.
RESULTS: We report that the calcium-activated protein phosphatase CaN (calcineurin), its endogenous inhibitory protein carabin, the STK24 (STE20-like protein kinase 3), and the histone monomethyltransferase, MLL3 (mixed lineage leukemia 3) form altogether a macromolecular complex at the chromatin of cardiomyocytes. Under basal conditions, carabin prevents CaN activation while the serine/threonine kinase STK24 maintains MLL3 inactive via phosphorylation. After 1 week of transverse aortic constriction, both carabin and STK24 are released from the CaN-MLL3 complex leading to the activation of CaN, dephosphorylation of MLL3, and in turn, histone H3 lysine 4 monomethylation. Selective cardiac MLL3 knockdown mitigates hypertrophy, and chromatin immunoprecipitation and DNA sequencing analysis demonstrates that MLL3 is de novo recruited at the transcriptional start site of genes implicated in cardiomyopathy in stress conditions. We also show that CaN and MLL3 colocalize at chromatin and that CaN activates MLL3 histone methyl transferase activity at distal intergenic regions under hypertrophic conditions.
CONCLUSIONS: Our study reveals an unsuspected epigenetic mechanism of CaN that directly regulates MLL3 histone methyl transferase activity to promote cardiac remodeling.
PURPOSE: A cosmetic composition formed in rouge or compact powder is provided to improve powder property and resistance to mechanical or thermal shock and to ensure persistence. CONSTITUTION: A solid cosmetic composition contains: 50-99 wt% of granulated solid phases; 0.1-50 wt% of one or more non-volatile liquid phases; 0.01-4 wt% of block copolymers prepared from 2-acrylamidomethyl propansulfonic acid or primary monomers of salt thereof, and vinyl secondary monomers with nitrogenous side chains. The granulated solid phase contains 25-35 wt% of spherical fillers. The secondary monomer is N-vinyl pyrrolidone. The composition also contains 0.1 wt% or less of fat substrate. A method for preparing the composition comprises: a step of mixing the solid phase, non-volatile liquid phase, block copolymers, and volatile liquid; a step of placing the mixture in a mold; and a step of partially removing the volatile liquid.
The invention provides a hair loss preventing and hair growing composition which comprises the following raw materials in percentage by weight: 0.1-30 wt% of bioactive silicon, 0-30 wt% of water-soluble nutrient substances, 0.1-37 wt% of pharmaceutic adjuvant and the balance of water. The bioactive silicon is an oxide containing 40-70 wt% of silicon dioxide and 30-60 wt% of phosphorus, calcium and sodium. The water-soluble nutrient comprises Chinese medicinal extract, high temperature resistant nutrient and non-high temperature resistant nutrient. The raw medicinal materials of the traditional Chinese medicine extract comprise: radix astragali, Mori fructus, radix Aconiti lateralis Preparata, rhizoma Zingiberis recens, Chinese arborvitae, radix rehmanniae Preparata, Saviae Miltiorrhizae radix, radix Paeoniae alba, rhizoma Ligustici Chuanxiong, cortex moutan, radix Paeoniae Rubra, radix Sophorae Flavescentis, cortex Cinchonae, Polygoni Multiflori radix, fructus Vitics Simplicifoliae, cimicifugae rhizoma, fructus Gleditsiae Abnormalis, folium Pini, herba Lycopi, and radix Allii Tuberosi. The medicinal adjuvants include gel, humectant, emulsifier, and oil. The invention also provides a preparation method of the hair loss preventing and hair growing composition. The alopecia preventing and hair growing composition can effectively treat alopecia.
A panel of IgG1 human monoclonal antibodies (HMAbs) identified by hemagglutination inhibition (HI) assay has been produced from peripheral B cells of an individual immunized with prototype H5N1 vaccine. Sequence analysis of antibody clones showed three clusters of different HMAbs as represented by HMAbs designated as BF1-1, BF1-19 and BF1-10. BF1-1 and BF1-10 have distinct CDR 1, 2 and 3 regions of both heavy and light chains. BF1-19 has the same heavy chain as BF1-1 but the light chain of BF1-10. Antibody binding affinity, KD, studies showed all three HMAbs ranging from at least about 10-8 to at least about 10-9.In vivo protection studies showed that these antibodies afforded significant protection against infection. These findings demonstrate that the antibodies of the invention are cross-neutralizing and therapeutic.
Participants will undergo real-time fMRI neurofeedback training to increase their amygdala response while recalling positive autobiographical memories. 2 sessions will occur within a one week period.
FIELD: medicine, complex homeopathic drugs. SUBSTANCE: homeopathic drug "Vozraston" has Ambra grisea, Aurum jodatum and Causticum hahnemanni taken at equal mass ratio of components. Drug "Vozraston" is prepared as granules saturated with spirituous 1:100 dilution of the following components by homeopathic procedures: Ambria grisea C50; Aurum jodatum C30, and Causticum hahnemanni C200. The agent provides an effective treatment of patients with neuroso-like disorders associated with vascular pathology of the brain. The agent can be used for treatment of patients with neurotic disorders at early stage of atherosclerosis in human of elderly and senile age. EFFECT: enhanced effectiveness of drug. 2 cl, 1 ex
In the NSABP P-1 Trial, there was an increase in five serious adverse effects in the tamoxifen group: endometrial cancer (33 cases in the tamoxifen group vs. 14 in the placebo group); pulmonary embolism (18 cases in the tamoxifen group vs. six in the placebo group); deep vein thrombosis (30 cases in the tamoxifen group vs. 19 in the placebo group); stroke (34 cases in the tamoxifen group vs. 24 in the placebo group); cataract formation (540 cases in the tamoxifen group vs. 483 in the placebo group) and cataract surgery (101 cases in the tamoxifen group vs. 63 in the placebo group) (see WARNINGS and CLINICAL PHARMACOLOGY: Table 3).

The following table presents the adverse events observed in NSABP P-1 by treatment arm. Only adverse events more common on tamoxifen than placebo are shown.

In the NSABP P-1 trial, 15% and 9.7% of participants receiving tamoxifen and placebo therapy, respectively withdrew from the trial for medical reasons. The following are the medical reasons for withdrawing from tamoxifen and placebo therapy, respectively: Hot Flashes 3.1% vs. 1.5%) and Vaginal Discharge (0.5% vs. 0.1%).

In the NSABP P-1 trial, 8.7% and 9.6% of participants receiving tamoxifen and placebo therapy, respectively withdrew for non-medical reasons.

On the NSABP P-1 trial, hot flashes of any severity occurred in 68% of women on placebo and in 80% of women on tamoxifen. Severe hot flashes occurred in 28% of women on placebo and 45% of women on tamoxifen. Vaginal discharge occurred in 35% and 55% of women on placebo and tamoxifen respectively; and was severe in 4.5% and 12.3% respectively. There was no difference in the incidence of vaginal bleeding between treatment arms.
The interventional group (n=22) will receive TENS sessions in addition to the prescribes medication (Gabapentinoids). The assessment will be performed at three time points also; before the begging of the intervention, after 5 days, and after the last session.
This application concerns a preparation for the production of agents for bleaching and lightening hair presented in solid form, whereby mixtures of granulates of the individual components are used or at least the persulphates contained therein are in granular form. Granulation may be achieved by the ordinary technical processes, e.g. spray-drying, in which wetting agents, emulsifiers or thickeners may be added to the initial substances before granulation. The preparation described is distinguished by good shelf-life and avoids the previous drawbacks of lightening agents, e.g. separation or varying chemical composition through loss of ammonia. The application also covers a 2-part agent and a process for bleaching and lightening hair using the aforementioned preparation.
The present invention relates generally to a method of modulating cellular activity and to agents for use therein. More particularly, the present invention provides a method of modulating the level of sphingosine kinase functional activity. In a related aspect, the present invention provides a method of modulating sphingosine kinase mediated signalling via modulation of its intracellular level of activity. The present invention still further extends to novel molecules which exhibit the capacity to induce sphingosine kinase activity. The methods and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate cellular functional activity and/or aberrant, unwanted or otherwise inappropriate sphingosine kinase mediated signalling. The present invention is further directed to methods for identifying and/or designing agents capable of modulating the level of sphingosine kinase activity.
Chromogranin A (CgA), a ∼ 49 kDa acidic secretory protein, is ubiquitously distributed in endocrine and neuroendocrine cells and neurons. As a propeptide, CgA is proteolytically cleaved to generate several peptides of biological importance, including pancreastatin (PST: hCgA250-301), Vasostatin 1 (VS1: hCgA1-76), and catestatin (CST: CgA 352-372). VS1 represents the most conserved fragment of CgA. A 20 amino acid domain within VS1 (CgA 47-66) exhibits potent antimicrobial and anti-inflammatory activities. Autism is known to be associated with inflammation. Therefore, we seek to test the hypothesis that VS1 modulates autism behaviors by reducing inflammation in the hippocampus. Treatment of C57BL/6 (B6) and BTBR (a mouse model of idiopathic autism) mice with VS1 revealed the following: BTBR mice showed a significant decrease in chamber time in the presence of a stranger or a novel object. Treatment with VS1 significantly increased chamber time in both cases, underscoring a crucial role for VS1 in improving behavioral deficits in BTBR mice. In contrast to chamber time, sniffing time in BTBR mice in the presence of a stranger was less compared to B6 control mice. VS1 did not improve this latter parameter. Surprisingly, sniffing time in BTBR mice in the presence of a novel object was comparable with B6 mice. Proinflammatory cytokines such as IL-6 and IL-1b, as well as other inflammatory markers, were elevated in BTBR mice, which were dramatically reduced after supplementation with VS1. Interestingly, even Beclin-1/p62, pAKT/AKT, and p-p70-S6K/p70-S6K ratios were notably reduced by VS1. We conclude that VS1 plays a crucial role in restoring autistic spectrum disorders (ASD) plausibly by attenuating neuroinflammation.
The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 and Day 15 of each 28-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional). The 5-FU IV bolus (400 mg/m2) and CIV infusion (2400 mg/m2) over 46 hours is repeated on Days 15 and 16 of each cycle.